Managing Vasomotor Symptoms at Menopause: Clinical Vignettes

Article Type: Editorial
Authors: Ritu Sharma, Pikee Saxen


Vasomotor symptoms (VMS) of varying intensity and frequency mark transition from premenopausal to perimenopausal period. The management needs to be individualized and shared decision making is advocated. For postmenopausal women with mild VMS lifestyle changes may be of help; while for moderate to severe VMS, systemic MHT shows the best results. In patients without uterus, Estrogen only therapy/ET is preferred; while in patients with uterus, estrogen progestogen therapy EPT is recommended to avoid estrogen-associated endometrial hyperplasia and risk of malignancy. Lowest effective dose of MHT for 3–5 years is usually required for women <60 years or within 10 years of menopause onset with nocontraindications. If MHT is contraindicated or not acceptable, SSRI, SNRI, gabapentin, pregabalin are the alternative options available; and if all are contraindicated, trial of clonidine is suggested. The complementary and alternate therapy are not recommended owing to lack of consistent evidence.

Keywords: Vasomotor symptoms (VMS); Menopausal hormone therapy (MHT); Estrogen only therapy (ET); Estrogen progestogen therapy (EPT); Conjugated equine estrogen (CEE).
Issue Number: Issue - 3   September - December 2022
Pages: 97 - 138
Full text PDF

© 2018 | PAJOG All rights reserved.